Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Netherlands

We work for top 100 enterprise. For example farmaceutical companies ranked in the global top 20. Furthermore, nine out of ten of the global producers of medical instruments are part of our client base. To our lawyers – who often have an in-house history in your industry themselves – your industry has no secrets. The marketing of medicinal products. Public procurement. Pricing and reimbursement. The protection of patents. Or agreements for clinical trials. We know what you are talking about. That is why we assist our top clients with their strategic decisions, the structuring of their business transactions and in legal proceedings.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology and medical devices. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

"The CMS team offers a broad range of expertise including regulatory, IP, and competition."

The Legal 500, 2019

"They are very well connected with their team; they really use the benefit of working together in their various offices."

Chambers Global, 2019

"Extremely responsive and overall always felt that I was in extremely safe hands."

Chambers Global, 2019

A client describes the lawyers as "subject matter experts".

Chambers Europe, 2019

Clients praise the firm's international network as a key advantage, particularly appreciating that "it is able to provide expertise across multiple jurisdictions. This co-operation is done in a very expedient and uncomplicated manner."

Chambers Europe, 2019

In M&A the firm has a good reputation for working in the hospitality, life sciences and oil and gas sectors.

IFLR1000, 2019

"They always provide good advice that's commercially sound and legally accurate."

Chambers Global, 2018

"Great knowledge and geographical coverage across Europe."

Chambers Global, 2018

"The client service and responsiveness are exceptional."

Chambers Europe, 2018

Choose area

    Pharmaceuticals

    Pharmaceutical and healthcare law focuses on all the special legislation and legal aspects to do with medicine provision, biotechnology and healthcare. Whether it concerns manufacturing, operations, licences, rates, quality, market regulation or care insurance, there is specific legislation for all these areas.

    Read more
    02/04/2019
    WLG Can­nabis Leg­al­iz­a­tion: Europe Up­date
    Pod­cast
    Sub­scribe to Life Sci­ences & Health­care top­ics
    September 2019
    CMS Life Sci­ences & Health­care Glob­al Bro­chure

    Feed

    Show only
    05 Dec 19
    A leg­al roadmap for Can­nabis 2019
    15 Nov 19
    Brexit and data pro­tec­tion: what to do next (when you don’t know what’s...
    Whilst the threat of a no-deal Brexit has been aver­ted for now, the fu­ture is by no means cer­tain. We have high­lighted some of the key is­sues for UK-based or­gan­isa­tions, and the EEA or­gan­isa­tions that...
    September 2019
    CMS Life Sci­ences & Health­care Glob­al Bro­chure
    05 Nov 19
    Whis­tleblow­ing Dir­ect­ive ad­op­ted by the EU Coun­cil
    On 7 Oc­to­ber 2019, the EU Coun­cil ap­proved the word­ing of the "Dir­ect­ive of the European Par­lia­ment and of the Coun­cil on the pro­tec­tion of per­sons who re­port breaches of Uni­on law", also known as the...
    August 2019
    Dop­ing is dam­aging es­ports
    13 Sep 19
    SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
    Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...
    25 June 2019
    AI in Life Sci­ences
    Leg­al per­spect­ives on the op­por­tun­it­ies and chal­lenges...
    13 Jun 19
    SPC Man­u­fac­tur­ing Waiver to come in­to ef­fect 1 Ju­ly 2019
    Gen­er­ics com­pan­ies will soon be able to man­u­fac­ture SPC-pro­tec­ted drugs for ex­port out­side the EU un­der new man­u­fac­tur­ing waiver pro­vi­sions. In the last six months of the SPC life­time, it will also be...
    Sep 2018
    Di­git­isa­tion in health­care: From uto­pia to real­ity...
    #law­volu­tion
    30 May 19
    EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from...
    The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc.'s European pat­ent ap­plic­a­tion (EP07837908.8), the claimed chem­ic­al...
    June 2018
    De­liv­er­ing qual­ity ad­vice you can act on
    An­nu­al Re­view 2017 – 2018
    27 Mar 19
    Judg­ment on Ab­rax­is C-443/17; 21st March 2019
    The CJEU de­livered its judg­ment last week on the case of Ab­rax­is v Comp­troller Gen­er­al of Pat­ents con­cern­ing Sup­ple­ment­ary Pro­tec­tion Cer­ti­fic­ates (SPCs) for new for­mu­la­tions of medi­cin­al products. The...